262 related articles for article (PubMed ID: 31369907)
21. Insights on the interaction of alpha-synuclein and metals in the pathophysiology of Parkinson's disease.
Carboni E; Lingor P
Metallomics; 2015 Mar; 7(3):395-404. PubMed ID: 25648629
[TBL] [Abstract][Full Text] [Related]
22. Interaction of alpha-synuclein and dopamine metabolites in the pathogenesis of Parkinson's disease: a case for the selective vulnerability of the substantia nigra.
Galvin JE
Acta Neuropathol; 2006 Aug; 112(2):115-26. PubMed ID: 16791599
[TBL] [Abstract][Full Text] [Related]
23. Alpha-Synuclein Oligomers Interact with Metal Ions to Induce Oxidative Stress and Neuronal Death in Parkinson's Disease.
Deas E; Cremades N; Angelova PR; Ludtmann MH; Yao Z; Chen S; Horrocks MH; Banushi B; Little D; Devine MJ; Gissen P; Klenerman D; Dobson CM; Wood NW; Gandhi S; Abramov AY
Antioxid Redox Signal; 2016 Mar; 24(7):376-91. PubMed ID: 26564470
[TBL] [Abstract][Full Text] [Related]
24. Iron and dopamine: a toxic couple.
Hare DJ; Double KL
Brain; 2016 Apr; 139(Pt 4):1026-35. PubMed ID: 26962053
[TBL] [Abstract][Full Text] [Related]
25. Increased nigral iron content and alterations in other metal ions occurring in brain in Parkinson's disease.
Dexter DT; Wells FR; Lees AJ; Agid F; Agid Y; Jenner P; Marsden CD
J Neurochem; 1989 Jun; 52(6):1830-6. PubMed ID: 2723638
[TBL] [Abstract][Full Text] [Related]
26. Metals associated neurodegeneration in Parkinson's disease: Insight to physiological, pathological mechanisms and management.
Raj K; Kaur P; Gupta GD; Singh S
Neurosci Lett; 2021 May; 753():135873. PubMed ID: 33812934
[TBL] [Abstract][Full Text] [Related]
27. [Morphochemical study of alpha-synuclein, iron and iron-containing proteins in the substantia nigra of the brain in Parkinson's disease].
Salkov VN; Khudoerkov RM; Voronkov DN; Sobolev VB
Arkh Patol; 2022; 84(2):13-19. PubMed ID: 35417944
[TBL] [Abstract][Full Text] [Related]
28. Altered mitochondrial function, iron metabolism and glutathione levels in Parkinson's disease.
Jenner P
Acta Neurol Scand Suppl; 1993; 146():6-13. PubMed ID: 8333254
[TBL] [Abstract][Full Text] [Related]
29. Neuromelanin can protect against iron-mediated oxidative damage in system modeling iron overload of brain aging and Parkinson's disease.
Zecca L; Casella L; Albertini A; Bellei C; Zucca FA; Engelen M; Zadlo A; Szewczyk G; Zareba M; Sarna T
J Neurochem; 2008 Aug; 106(4):1866-75. PubMed ID: 18624918
[TBL] [Abstract][Full Text] [Related]
30. Alterations in the levels of iron, ferritin and other trace metals in Parkinson's disease and other neurodegenerative diseases affecting the basal ganglia.
Dexter DT; Carayon A; Javoy-Agid F; Agid Y; Wells FR; Daniel SE; Lees AJ; Jenner P; Marsden CD
Brain; 1991 Aug; 114 ( Pt 4)():1953-75. PubMed ID: 1832073
[TBL] [Abstract][Full Text] [Related]
31. Iron accumulation in Parkinson's disease.
Mochizuki H; Yasuda T
J Neural Transm (Vienna); 2012 Dec; 119(12):1511-4. PubMed ID: 23070727
[TBL] [Abstract][Full Text] [Related]
32. Impaired mitochondrial dynamics and function in the pathogenesis of Parkinson's disease.
Büeler H
Exp Neurol; 2009 Aug; 218(2):235-46. PubMed ID: 19303005
[TBL] [Abstract][Full Text] [Related]
33. The impact of reactive oxygen species and genetic mitochondrial mutations in Parkinson's disease.
Zuo L; Motherwell MS
Gene; 2013 Dec; 532(1):18-23. PubMed ID: 23954870
[TBL] [Abstract][Full Text] [Related]
34. Glial reactions in Parkinson's disease.
McGeer PL; McGeer EG
Mov Disord; 2008 Mar; 23(4):474-83. PubMed ID: 18044695
[TBL] [Abstract][Full Text] [Related]
35. Iron metabolism and Parkinson's disease.
Hirsch EC; Faucheux BA
Mov Disord; 1998; 13 Suppl 1():39-45. PubMed ID: 9613717
[TBL] [Abstract][Full Text] [Related]
36. Dopamine complexes of iron in the etiology and pathogenesis of Parkinson's disease.
Arreguin S; Nelson P; Padway S; Shirazi M; Pierpont C
J Inorg Biochem; 2009 Jan; 103(1):87-93. PubMed ID: 18976814
[TBL] [Abstract][Full Text] [Related]
37. The enigma of neuromelanin in Parkinson's disease substantia nigra.
Youdim MB; Ben-Shachar D; Riederer P
J Neural Transm Suppl; 1994; 43():113-22. PubMed ID: 7884393
[TBL] [Abstract][Full Text] [Related]
38. Neuromelanin in Parkinson's Disease: from Fenton Reaction to Calcium Signaling.
Knörle R
Neurotox Res; 2018 Feb; 33(2):515-522. PubMed ID: 28879408
[TBL] [Abstract][Full Text] [Related]
39. Human alpha-synuclein over-expression increases intracellular reactive oxygen species levels and susceptibility to dopamine.
Junn E; Mouradian MM
Neurosci Lett; 2002 Mar; 320(3):146-50. PubMed ID: 11852183
[TBL] [Abstract][Full Text] [Related]
40. Selectivity of melaninized nigra-striatal dopamine neurons to degeneration in Parkinson's disease may depend on iron-melanin interaction.
Ben-Shachar D; Youdim MB
J Neural Transm Suppl; 1990; 29():251-8. PubMed ID: 2193109
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
